Logo 1200x628.jpg
FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review
22 oct. 2024 07h00 HE | CytoSorbents
FDA Accepts DrugSorb-ATR De Novo Application To Reduce CABG-Related Bleeding Severity Due To Brilinta, Starting Substantive Review, 2025 Decision Expected
Logo 1200x628.jpg
CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference
27 août 2024 07h00 HE | CytoSorbents
PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Logo 1200x628.jpg
CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
13 août 2024 16h19 HE | CytoSorbents
New CFO Peter J. Mariani to succeed retiring CFO Kathleen P. BlochOn track for DrugSorb™-ATR U.S. FDA De Novo and Health Canada marketing submissions this quarterIn Q2 2024, increased product sales by...
Logo 1200x628.jpg
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
13 août 2024 16h18 HE | CytoSorbents
PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery...
Logo 1200x628.jpg
CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
07 août 2024 07h00 HE | CytoSorbents
CytoSorbents to Report Q2 2024 Financial and Operating Results
Logo 1200x628.jpg
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
05 juin 2024 07h00 HE | CytoSorbents
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
Logo 1200x628.jpg
CytoSorbents STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024. Named Top Five Finalist for Best Scientific Abstract
04 juin 2024 07h00 HE | CytoSorbents
CTSO STAR Registry Data on Patients on Ticagrelor Undergoing CABG Surgery with CytoSorb Presented at EuroPCR 2024
Logo 400x400.jpg
CytoSorbents Reports First Quarter 2024 Results
09 mai 2024 16h17 HE | CytoSorbents
CytoSorbents Reports First Quarter 2024 Results
Logo 400x400.jpg
CytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
02 mai 2024 07h00 HE | CytoSorbents
CytoSorbents to Host Virtual KOL and Analyst-Investor Day on May 6, 2024 to review U.S. and Canada STAR-T Pivotal Trial Topline Results
Logo 400x400.jpg
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
26 avr. 2024 07h00 HE | CytoSorbents
CytoSorbents to Report First Quarter 2024 Operating and Financial Results